Pharmacologic Stress Using Selective A2A Adenosine Receptor Agonists

Robert Hendel, Niberto A. Moreno, David K. Glover

Research output: Contribution to journalArticle

Abstract

Adenosine and dipyridamole are nonselective A2A adenosine receptor agonists that provide reproducible coronary vasodilation thereby inducing flow disparities in the setting of physiologically important coronary stenosis. Although myocardial perfusion imaging in conjunction with pharmacologic stress with both agents has yielded high diagnostic accuracy and overall safety, limitations include concerns in selected populations, such as those with bronchospastic lung disease and heart block, frequent side effects, and a complicated method of delivery (sustained intravenous infusion). Regadenoson, binodenoson, and apadenoson are selective A2A adenosine receptor agonists that have been shown to provide more selective coronary vasodilatation, with improved safety profiles and patient tolerability. Additionally, these new agents may be delivered by an intravenous bolus eliminating the requirement for an infusion pump. Regadenoson is already in widespread clinical use in the United States. Binodenoson completed phase 3 clinical trials but has not yet been approved for clinical use. Apadenoson is currently in pivotal phase 3 clinical trials.

Original languageEnglish
Pages (from-to)217-226
Number of pages10
JournalCurrent Cardiovascular Imaging Reports
Volume4
Issue number3
DOIs
StatePublished - Dec 1 2011

Fingerprint

Adenosine A2 Receptor Agonists
Phase III Clinical Trials
Vasodilation
Infusion Pumps
Myocardial Perfusion Imaging
Heart Block
Dipyridamole
Coronary Stenosis
Patient Safety
Intravenous Infusions
Adenosine
Lung Diseases
Safety
Population
binodenoson
regadenoson

Keywords

  • Adenosine
  • Adenosine receptor agonist
  • Apadenoson
  • Binodenoson
  • Diagnosis
  • Pharmacologic stress
  • Regadenoson
  • Selective A adenosine receptor agonist
  • SPECT
  • Stress radionuclide myocardial perfusion imaging

ASJC Scopus subject areas

  • Cell Biology
  • Histology
  • Applied Microbiology and Biotechnology

Cite this

Pharmacologic Stress Using Selective A2A Adenosine Receptor Agonists. / Hendel, Robert; Moreno, Niberto A.; Glover, David K.

In: Current Cardiovascular Imaging Reports, Vol. 4, No. 3, 01.12.2011, p. 217-226.

Research output: Contribution to journalArticle

Hendel, Robert ; Moreno, Niberto A. ; Glover, David K. / Pharmacologic Stress Using Selective A2A Adenosine Receptor Agonists. In: Current Cardiovascular Imaging Reports. 2011 ; Vol. 4, No. 3. pp. 217-226.
@article{8c3dc4f1f70b4c4293cee65a6914be36,
title = "Pharmacologic Stress Using Selective A2A Adenosine Receptor Agonists",
abstract = "Adenosine and dipyridamole are nonselective A2A adenosine receptor agonists that provide reproducible coronary vasodilation thereby inducing flow disparities in the setting of physiologically important coronary stenosis. Although myocardial perfusion imaging in conjunction with pharmacologic stress with both agents has yielded high diagnostic accuracy and overall safety, limitations include concerns in selected populations, such as those with bronchospastic lung disease and heart block, frequent side effects, and a complicated method of delivery (sustained intravenous infusion). Regadenoson, binodenoson, and apadenoson are selective A2A adenosine receptor agonists that have been shown to provide more selective coronary vasodilatation, with improved safety profiles and patient tolerability. Additionally, these new agents may be delivered by an intravenous bolus eliminating the requirement for an infusion pump. Regadenoson is already in widespread clinical use in the United States. Binodenoson completed phase 3 clinical trials but has not yet been approved for clinical use. Apadenoson is currently in pivotal phase 3 clinical trials.",
keywords = "Adenosine, Adenosine receptor agonist, Apadenoson, Binodenoson, Diagnosis, Pharmacologic stress, Regadenoson, Selective A adenosine receptor agonist, SPECT, Stress radionuclide myocardial perfusion imaging",
author = "Robert Hendel and Moreno, {Niberto A.} and Glover, {David K.}",
year = "2011",
month = "12",
day = "1",
doi = "10.1007/s12410-011-9086-4",
language = "English",
volume = "4",
pages = "217--226",
journal = "Current Cardiovascular Imaging Reports",
issn = "1941-9066",
publisher = "Current Medicine Group",
number = "3",

}

TY - JOUR

T1 - Pharmacologic Stress Using Selective A2A Adenosine Receptor Agonists

AU - Hendel, Robert

AU - Moreno, Niberto A.

AU - Glover, David K.

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Adenosine and dipyridamole are nonselective A2A adenosine receptor agonists that provide reproducible coronary vasodilation thereby inducing flow disparities in the setting of physiologically important coronary stenosis. Although myocardial perfusion imaging in conjunction with pharmacologic stress with both agents has yielded high diagnostic accuracy and overall safety, limitations include concerns in selected populations, such as those with bronchospastic lung disease and heart block, frequent side effects, and a complicated method of delivery (sustained intravenous infusion). Regadenoson, binodenoson, and apadenoson are selective A2A adenosine receptor agonists that have been shown to provide more selective coronary vasodilatation, with improved safety profiles and patient tolerability. Additionally, these new agents may be delivered by an intravenous bolus eliminating the requirement for an infusion pump. Regadenoson is already in widespread clinical use in the United States. Binodenoson completed phase 3 clinical trials but has not yet been approved for clinical use. Apadenoson is currently in pivotal phase 3 clinical trials.

AB - Adenosine and dipyridamole are nonselective A2A adenosine receptor agonists that provide reproducible coronary vasodilation thereby inducing flow disparities in the setting of physiologically important coronary stenosis. Although myocardial perfusion imaging in conjunction with pharmacologic stress with both agents has yielded high diagnostic accuracy and overall safety, limitations include concerns in selected populations, such as those with bronchospastic lung disease and heart block, frequent side effects, and a complicated method of delivery (sustained intravenous infusion). Regadenoson, binodenoson, and apadenoson are selective A2A adenosine receptor agonists that have been shown to provide more selective coronary vasodilatation, with improved safety profiles and patient tolerability. Additionally, these new agents may be delivered by an intravenous bolus eliminating the requirement for an infusion pump. Regadenoson is already in widespread clinical use in the United States. Binodenoson completed phase 3 clinical trials but has not yet been approved for clinical use. Apadenoson is currently in pivotal phase 3 clinical trials.

KW - Adenosine

KW - Adenosine receptor agonist

KW - Apadenoson

KW - Binodenoson

KW - Diagnosis

KW - Pharmacologic stress

KW - Regadenoson

KW - Selective A adenosine receptor agonist

KW - SPECT

KW - Stress radionuclide myocardial perfusion imaging

UR - http://www.scopus.com/inward/record.url?scp=84873034129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873034129&partnerID=8YFLogxK

U2 - 10.1007/s12410-011-9086-4

DO - 10.1007/s12410-011-9086-4

M3 - Article

VL - 4

SP - 217

EP - 226

JO - Current Cardiovascular Imaging Reports

JF - Current Cardiovascular Imaging Reports

SN - 1941-9066

IS - 3

ER -